where experts go to learn about the FDA
FDA Law Blog where experts go to learn about FDA
Hyman, Phelps & McNamara, P.C.
Menu
Menu
  • Practices
  • Industries
  • FDA Regulatory Categories
  • Professionals
  • About Us
  • Contact
  • LinkedIn
  • Twitter
FDA Law Blog
News & Events
  • LinkedIn
  • Twitter
  • Recent Posts
    • Last One Standing: DOJ Narrows Fraud Enforcement Priorities to Companies that Violate the CSA and FDC Act October 6, 2026
    • Another Win for HCT/P Manufacturers: Court Vacates and Remands FDA’s AXIOFILL Determination October 2, 2026
    • Common Regulatory Deficiencies of Hospital Employee Diversion September 27, 2026
    • Nothing to See Here: FDA Issues Interchangeable Biosimilars Strategy Document September 25, 2026
    • T Time: Women Were First to Put Testosterone Back on FDA’s Agenda. Now It’s Industry’s Turn September 23, 2026
  • Trackers
    • 180-Day Exclusivity Tracker
    • FDA Citizen Petition Tracker
    • REMS Tracker (Historical – Not Recently Updated)
    • FDA Legislation Tracker
  • Orange Book Archives

     

    ANDA Paragraph IV Patent Certifications List Archives

  • Scorecards
    • Generic Drug Labeling Carve-Out Scorecard
    • Biosimilars State Legislation Scorecard (Historical – Not Recently Updated) 
  • Blogroll
    • Big Molecule Watch Blog
    • Bloomberg BNA Health Care Blog
    • Drug and Device Law Blog
    • Eye on FDA
    • FDA Matters
    • Harvard Law Bill of Health
    • IN VIVO Blog
    • Internet Drug News.com
    • Lachman Consultants Blog
    • Medical Devices Today
    • Orange Book Blog
    • The Orange Book Insights Blog
    • Pharma IQ
    • Pharmalot
    • SCOTUS Blog
    • The Volokh Conspiracy
    • WLF Legal Pulse
  • Resources
    • Centers for Medicare & Medicaid Services
    • Drug Enforcement Administration
    • Food and Drug Administration
  • Categories
    • Advertising and Promotion (Federal Trade Commission)
    • Advertising and Promotion (OPDP)
    • Animal Drugs and Feeds
    • Biosimilars
    • Cannabis
    • cGMP Compliance
    • Consumer Product Safety Commission
    • Controlled Substances
    • Cosmetics
    • COVID19
    • Current Affairs
    • Dietary Supplements
    • Drug Development
    • Drug Enforcement Administration
    • Enforcement
    • FDA News
    • Foods
    • Foods and Dietary Supplements
    • Fraud and Abuse
    • Government Pricing
    • Hatch-Waxman
    • Health Care
    • Health Privacy
    • Import/Export
    • In Vitro Diagnostic Devices
    • Jobs
    • Medical Devices
    • Miscellaneous
    • Orphan Drugs
    • OTC Drugs and Cosmetics
    • Prescription Drugs and Biologics
    • Product Jurisdiction and Combination Products
    • Reimbursement
    • Tissue Products
    • Tobacco
    • Uncategorized
  • Your search for “Reliable HL7-FHIR Dumps - HL7 HL7 FHIR STU3 Proficiency Realistic Reliable Dumps Pass Guaranteed 💦 Open website ➠ www.pdfvce.com 🠰 and search for ➥ HL7-FHIR 🡄 for free download 🧐HL7-FHIR Reliable Test Labs” returned the following results.

    FTC Settlement Silences Advertisers of Supplements Advertised as Effective for Children’s Speech Disorders; Settlement Silent on the Number of RCTs Required

    …will be enjoined from making advertising claims for Defendants’ speech products unless they possess competent and reliable scientific evidence to support the claims.  For the speech products,  “competent and reliable…

    Bayer Case Highlights the Importance of Involving an Expert in Substantiation

    …FTC case law beyond this order – defines “competent and reliable scientific evidence” specifically based on the “expertise of professionals in the relevant area.”  (The Bayer 2007 order defines “competent…

    Sunshine Reporting Registration to Open February 18

    By Jennifer D. Newberger & Alan M. Kirschenbaum – Last Friday, CMS issued a notice announcing the opening of registration for electronic Open Payments reporting under the physician payment sunshine…

    Seventh Circuit Rules That FTC Act Does Not Require Placebo-Controlled, Double-Blind Testing for Consumer Products

    …criteria that evidence must meet in order to be deemed reliable, other than to note that “a statement that is plausible but has not been tested in the most reliable…

    CDC Opioid Prescribing Guidelines; Excluding Stakeholders is Wrong Path

    …component within the U.S. Department of Health and Human Services, is developing guidelines “to provide recommendations for the prescribing of opioid pain medication for patients 18 and older in primary…

    Patent Settlement Agreements: The Next Barrage

    By Kurt R. Karst –       In our recent post, “Hot Ticket Item – Patent Settlement Agreement Challenges,” we provided a round-up of the latest and greatest from ongoing litigation concerning…

    It’s All So Simple Now: The First Traditional Marketing Authorization for a Non-PCR Based Test to Detect SARS-CoV-2

    …marketing authorization for a non-PCR based test to detect SARS-CoV-2. The authorization of this De Novo, with a formal classification of Class II, now opens the door for follow-up 510(k)…

    FDA Issues Proposed List of Class II Devices for 510(k) Exemption – Focus on IVDs, Including Drugs-of-Abuse Tests

    …some over-the-counter tests. The proposed exemption for drugs-of-abuse test systems is limited to “test systems intended for employment and insurance testing and does not include test systems intended for Federal…

    A New FDA Tobacco Enforcement Guidance Lawsuit: AAP Déjà Vu All Over Again, or Not?

    …list. That’s what a recently filed case is about, Campaign for Tobacco-Free Kids v. FDA, No. 8:26-cv-2767 (D. Md., filed July 14, 2026). There, Tobacco-Free Kids, along with the American…

    Long-Awaited Guidance on FDAMA 115: Confirmatory Evidence Finally Has Its Moment (to be Crossed Off the FDA’s Guidance To-Do List)

    …of FDA’s factors above and, yet, not be able to pass this translational test because there may no prior drugs developed to demonstrate the animal model’s translational ability. Such circumstances…

    The Court of Appeals for the D.C. Circuit Upholds FDA’s Deeming Rule

    …of free samples. As we previously blogged here, on the same day FDA issued this final deeming rule, Nicopure Labs, Inc. (“Nicopure”) filed a complaint in the D.C. District Court…

    Highlights of Medical Device Related Provision in the 21st Century Cures Act

    …products. If you have questions or need more information, contact: Jeffrey K. Shapiro, jshapiro@hpm.com, 202-737-9633 Jeffrey N. Gibbs, jgibbs@hpm.com, 202-737-4288 Jennifer D. Newberger, jnewberger@hpm.com, 202-737-4292 Allyson B. Mullen, amullen@hpm.com, 202-737-9639…

    FDA’s Latest Lists for Digital Health Technologies

    …device name, company name, lead review panel (e.g., radiology or cardiovascular), and primary product code. They provide a search bar to help find specific products and also include options to…

    180-Day Exclusivity – From Abacavir Sulfate to Zolpidem Tartrate

    …list.  Like all things Hatch-Waxman, it is quite complicated and takes a lot of time to figure out.  Imagine, if you will, coming across a cache of 5,000-piece puzzles in…

    FDA Issues “Receipt Date” Guidance for Electronic Submissions; Make Your Submissions Before Midnight With Time to Spare

    …last to arrive is transmitted to the ESG and that transmission is completed at 11:55 pm EST, but that ANDA does not completely arrive at CDER until 12:01 am EST…

    Page 10 of 118« First«...91011...2030...»Last »

    Search FDA Law Blog

    Subscribe

    Never miss a post from FDA Law Blog







    Latest Tweets

    Tweets by @fdalawblog

    Awards & Honors

    • Best Lawyers in America® – 2026
    • Ranked in Chambers USA – 2025
  • Recent Posts
    • Last One Standing: DOJ Narrows Fraud Enforcement Priorities to Companies that Violate the CSA and FDC Act October 6, 2026
    • Another Win for HCT/P Manufacturers: Court Vacates and Remands FDA’s AXIOFILL Determination October 2, 2026
    • Common Regulatory Deficiencies of Hospital Employee Diversion September 27, 2026
    • Nothing to See Here: FDA Issues Interchangeable Biosimilars Strategy Document September 25, 2026
    • T Time: Women Were First to Put Testosterone Back on FDA’s Agenda. Now It’s Industry’s Turn September 23, 2026
  • Trackers
    • 180-Day Exclusivity Tracker
    • FDA Citizen Petition Tracker
    • REMS Tracker (Historical – Not Recently Updated)
    • FDA Legislation Tracker
  • Orange Book Archives

     

    ANDA Paragraph IV Patent Certifications List Archives

  • Scorecards
    • Generic Drug Labeling Carve-Out Scorecard
    • Biosimilars State Legislation Scorecard (Historical – Not Recently Updated) 
  • Blogroll
    • Big Molecule Watch Blog
    • Bloomberg BNA Health Care Blog
    • Drug and Device Law Blog
    • Eye on FDA
    • FDA Matters
    • Harvard Law Bill of Health
    • IN VIVO Blog
    • Internet Drug News.com
    • Lachman Consultants Blog
    • Medical Devices Today
    • Orange Book Blog
    • The Orange Book Insights Blog
    • Pharma IQ
    • Pharmalot
    • SCOTUS Blog
    • The Volokh Conspiracy
    • WLF Legal Pulse
  • Resources
    • Centers for Medicare & Medicaid Services
    • Drug Enforcement Administration
    • Food and Drug Administration
  • Categories
    • Advertising and Promotion (Federal Trade Commission)
    • Advertising and Promotion (OPDP)
    • Animal Drugs and Feeds
    • Biosimilars
    • Cannabis
    • cGMP Compliance
    • Consumer Product Safety Commission
    • Controlled Substances
    • Cosmetics
    • COVID19
    • Current Affairs
    • Dietary Supplements
    • Drug Development
    • Drug Enforcement Administration
    • Enforcement
    • FDA News
    • Foods
    • Foods and Dietary Supplements
    • Fraud and Abuse
    • Government Pricing
    • Hatch-Waxman
    • Health Care
    • Health Privacy
    • Import/Export
    • In Vitro Diagnostic Devices
    • Jobs
    • Medical Devices
    • Miscellaneous
    • Orphan Drugs
    • OTC Drugs and Cosmetics
    • Prescription Drugs and Biologics
    • Product Jurisdiction and Combination Products
    • Reimbursement
    • Tissue Products
    • Tobacco
    • Uncategorized
  • Copyright 2026 FDA Law Blog HPM
    • Disclaimer
    • Careers